Companies in the News

Vir Biotechnology: Fierce15 Winner

This quiet biotech is looking for curative therapies and new vaccines for a host of infectious diseases with an experienced biopharma executive team. CEO: George Scangos Based: San Francisco Founded: 2017 Clinical focus: Infectious diseases The scoop: When George Scangos stepped down as CEO of Biogen in late 2016, biotech fans wondered what he would do next. They didn’t have to wait long to get their answer: In January 2017, he reemerged as CEO of Vir Biotechnology, a startup focused on developing vaccines and drugs to cure infectious diseases whose treatments are scarce. The company is taking a multipronged approach to R&D that includes funding academic researchers, in-licensing novel

FierceBiotech Names Gritstone Oncology as a "Fierce 15" Biotechnology Company of 2017

Emeryville, CA, September 26, 2017 – Gritstone Oncology, a next-generation personalized cancer immunotherapy company, has been named by FierceBiotech as one of 2017’s Fierce 15 biotechnology companies, recognizing it as one of the most promising private biotechnology companies in the industry. Founded in October 2015, Gritstone Oncology is focused on understanding each patient’s tumor antigens at a molecular level, using deep learning techniques, and then developing immune therapies targeted to that specific set of tumor antigens. The goal is to make therapeutic immune attack highly specific to the tumor, sparing normal tissues, and reducing toxicity. Gritstone is building a pipeline of pers

BlackThorn Selected as a Fierce15 2017 Winner

BlackThorn Therapeutics has been selected as one of the “Fierce 15” winners for 2017. With this designation, BlackThorn is considered one of the “up-and-coming privately-held biotech companies expected to make big waves in the industry.” The annual Fierce 15 list celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. This year, FierceBiotech evaluated a record number of nominations submitted by readers and editors of the publication, and selected the winners based on a variety of factors, including strength of technology, partnerships, venture backers and a competitive market position. FierceBiotech’s full list of winners can

AgTech Startup Indigo Is Boston’s Newest Unicorn After $156M Series D

Boston-based Indigo announced Tuesday the first closing of $156 million in its Series D financing, doubling the company’s total capital raised to over $300 million. Since the latest round now has Indigo valued at $1.4 billion, according to a company spokesperson, the agriculture startup is officially Boston’s unicorn No. 7 – meaning it’s joining the club of private companies having valuations of at least $1 billion. The latest company that cleared the bar was Desktop Metal, thanks to its $115 million Series D in July. Indigo’s founder and first investor, Flagship Pioneering, and existing investor, the Alaska Permanent Fund, were joined in this round by new investors, including Baillie Giffor

Gritstone Oncology Secures $92.7 Million In Series B Financing

Proceeds Will Support Further Development of Proprietary Tumor Antigen Identification Platform and Advancement of Pipeline of Personalized Cancer Immunotherapies Lead Program Expected to Enter Clinical Trials in Mid-2018 Personalized Immunotherapy Manufacturing Facility Under Construction and will Provide Investigational Products for Clinical Trial Program Emeryville, CA, September 7, 2017 – Gritstone Oncology, a next-generation personalized cancer immunotherapy company, today announced the successful completion of a $92.7 million Series B preferred stock financing. Proceeds from the financing will be used to advance Gritstone’s tumor antigen identification platform and pipeline of personali